News

GlaxoSmithKline Pharmaceuticals (GSK) has reported its financial results for the third quarter ended September 2009. The company has reported 12% increase in net sales as compared to the

Affymax and Takeda Pharmaceutical (Takeda) have reported data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a phase 2 trial, which demonstrated that Hematide

NovaBay has announced that its Aganocide compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented at the

Sunesis Pharmaceuticals (Sunesis) has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial. Its a phase 2 dose regimen optimisation trial of single agent voreloxin

Geron is planning to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury. The plan is expected to

The FDA has issued a complete response letter to Schering-Plough’s supplemental Biologics License Application (BLA) regarding Pegintron (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage

Impax has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR (fenofibrate) tablets, 48 mg and 145 mg. Impax filed its abbreviated

China Medicine has reported that through its wholly-owned subsidiary, Konzern, it has signed an equity transfer agreement to acquire 100% of equity interests in Sinoform. Under the terms

FDA has sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally